about
Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literatureAnthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.Malignant cardiac tumors: diagnosis and treatment.Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature.Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach.Comment on "repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results": will there be clinical implications in the future?Autosomal dominant pseudohypoparathyroidism type Ib: a novel inherited deletion ablating STX16 causes loss of imprinting at the A/B DMR.Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.Gonadal agenesis with hypoplastic paramesonephric ducts (PMNDs) derivatives in dizygotic twins.Metabolomics biomarkers of frailty in elderly breast cancer patients.Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esophageal carcinoma following trimodality therapy: a case report.Quantitative Proteomic Approach Targeted to Fibrinogen β Chain in Tissue Gastric Carcinoma.Improved outcome with multimodal treatment and imatinib rechallenge in advanced GISTPhase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patientsWeekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?Rapid LC-MS/MS method for quantification of vinorelbine and 4-O-deacetylvinorelbine in human whole blood suitable to monitoring oral metronomic anticancer therapyCarcinogenesis and Metastasis in Liver: Cell Physiological BasisPolymorphism in Toll-Like Receptors and Helicobacter Pylori Motility in Autoimmune Atrophic Gastritis and Gastric CancerThe metabolomic scent of cancer disease progression in soft tissue sarcoma: A case reportA novel mosaic 1q32.1 microduplication identified through Chromosome Microarray Analysis: narrowing the smallest critical region including KDM5B gene found associated with neurodevelopmetal disordersCancer survivors: surveillance or not surveillance?[Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.]Role of Bruton's Tyrosine Kinase in Stage III Colorectal CancerComplete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases
P50
Q33578242-211E25AC-AB82-4BC3-8E3B-6519C5260869Q33629632-00071A9D-1071-4060-8633-4B602E071D31Q34996054-88832F2F-555E-419A-8AC9-EF7BEB715C73Q35789363-84CCFB54-24A8-497F-AECC-AEAFF4F3A512Q35916613-DD80F784-A787-4B24-AF16-F078CA791B19Q37457684-1F94709B-0D28-4280-B598-ED54D3B0FF92Q38559451-6D933F7F-74C3-40EA-A961-233D0324D366Q38652054-4A97887A-5737-4AF2-9F0F-B29A5ED2BC9CQ38832795-E8F8EF88-9985-4336-8A62-DFC5B7DB91E0Q39454037-6049F1E5-0120-4553-9969-4EC8D37B1447Q40811026-8BC86E37-3681-4888-B78B-3A276E99D97BQ41421332-B9266355-A8C5-4320-9E75-9859D7A3C101Q47218550-28D83824-5020-4B1A-807B-959518F1213CQ47409192-89C00AC0-AF47-42D0-9D7C-FE460DC9ED1DQ51443498-B6FFE228-ABA4-4AFF-99BC-900BA5540AABQ52646977-601565B2-6B87-4785-8AF8-16BC1344E663Q52666367-FC2F4398-9029-4DDB-A9B6-60A42E2D1C5DQ53010579-5CF6CD10-D4E5-4DF9-B835-BEF76578C589Q53061043-45CA68F5-BDF8-43BC-9CD4-911B7CACD589Q53128779-3CB3C6D6-0A0B-4D9F-A22F-EADEC169569AQ55195821-AFABB2CD-0A4D-4EF3-9C2A-B963FCF536F3Q58200823-4BA8DE13-CA1E-45F6-91B4-3BA8C463DE73Q60697885-D9F67B84-595C-43F6-BA3F-47996FCEA631Q84514196-696D5693-1185-4B9D-B688-5FCDA6BB4920Q88635481-52FDD354-3E4B-458C-9040-E121031F028BQ91147698-958A6E98-7C75-48FB-8346-0A08B6A668FEQ91981231-84633075-DD1E-4656-AD44-E9AA5C269694Q92249847-F3C0D523-7831-4F8A-ACAD-6B70A9419FB3Q92574048-DA3498D6-E128-4071-9E92-F6946A9CC72DQ92744019-D6748694-0F65-4512-954F-6F43962F3B02Q92994942-7FDA2E8E-84CC-42D7-B607-46E415C1DF37Q93017736-7B50E387-C4C0-4F4E-8A14-EE13271EC700Q93060450-DA6BA822-1B67-44EA-B0F8-6E82385496B0
P50
description
investigador
@es
researcher
@en
name
Gianmaria Miolo
@en
type
label
Gianmaria Miolo
@en
prefLabel
Gianmaria Miolo
@en
P31
P496
0000-0001-5084-295X